Outcomes of first-line (1L) ipilimumab and nivolumab (IPI-NIVO) and subsequent therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).

被引：1
|
作者：
Gan, Chun Loo
Wells, J. Connor
Schmidt, Andrew Lachlan
Powles, Thomas
Tran, Ben
Meza, Luis A.
Labaki, Chris
Lee, Jae-Lyun
Wood, Lori
Shapiro, Julia
Ernst, D. Scott
Kapoor, Anil
Canil, Christina M.
Yuasa, Takeshi
McKay, Rana R.
Beuselinck, Benoit
Donskov, Frede
Dudani, Shaan
Choueiri, Toni K.
Heng, Daniel Yick Chin
机构：
[1] Univ Calgary, Tom Baker Canc Ctr, Calgary, AB, Canada
[2] Univ Calgary, Calgary, AB, Canada
[3] Cairns & Hinterland Hosp & Hlth Serv, Liz Plummer Canc Ctr, Cairns, Qld, Australia
[4] Queen Mary Univ London, Royal Free Natl Hlth Serv Trust, Canc Res UK Expt Canc Med Ctr, Barts Canc Inst, London, England
[5] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[6] City Hope Comprehens Canc Ctr, Duarte, CA USA
[7] Dana Farber Canc Inst Individuals, Boston, MA USA
[8] Asan Med Ctr, Seoul, South Korea
[9] Univ Ulsan, Coll Med, Seoul, South Korea
[10] Dalhousie Univ, Halifax, NS, Canada
[11] Cabrini Hlth, Melbourne, Vic, Australia
[12] London Hlth Sci Ctr, London Reg Canc Program, Dept Oncol, Div Med Oncol, London, ON, Canada
[13] Univ Western Ontario, London, ON, Canada
[14] St Josephs Healthcare, McMaster Inst Urol, Hamilton, ON, Canada
[15] Univ Ottawa, Ottawa Hosp, Ottawa, ON, Canada
[16] Japanese Fdn Canc Res, Canc Inst Hosp, Tokyo, Japan
[17] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA
[18] Univ Ziekenhuizen, Leuven Canc Inst, Leuven, Belgium
[19] Aarhus Univ Hosp, Aarhus, Denmark
[20] Univ Ottawa, Ottawa Hosp Canc Ctr, Ottawa, ON, Canada
[21] Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.4554
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4554
引用
收藏
页数：4
相关论文
共 50 条
  • [31] The impact of impaired renal function on the effectiveness of first-line immuno-oncology combination therapies in metastatic renal cell carcinoma (mRCC): Results from the international metastatic RCC database consortium (IMDC)
    Navani, V.
    Ernst, M. S.
    Takemura, K.
    Pal, S. K.
    Powles, T. B.
    Donskov, F.
    Wells, J. C.
    Kollmannsberger, C. K.
    Beuselinck, B.
    Alva, A. S.
    Weickhardt, A. J.
    Lalani, A-K.
    Ernst, D. S.
    Agarwal, N.
    Choueiri, T. K.
    Heng, D. Y. C.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1215 - S1216
  • [32] Updated outcomes of patients with metastatic non-clear cell renal cell carcinoma (mnccRCC) treated with first-line (1L) therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
    Takemura, Kosuke
    Graham, Jeffrey
    Maj, David
    Zarba, Martin
    Wells, Connor
    Chehade, Razane El Hajj
    Eid, Marc
    Saad, Eddy
    Saliby, Renee Maria
    Lee, Jae Lyun
    Donskov, Frede
    Beuselinck, Benoit
    Jude, Evon
    McKay, Rana R.
    Basappa, Naveen S.
    Pal, Sumanta Kumar
    Porta, Camillo
    Agarwal, Neeraj
    Choueiri, Toni K.
    Heng, Daniel Yick Chin
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
  • [33] Updated results from a phase I study of nivolumab (Nivo) in combination with ipilimumab (Ipi) in metastatic renal cell carcinoma (mRCC): The CheckMate 016 study
    Hammers, H.
    Plimack, E. R.
    Infante, J. R.
    Rini, B. I.
    McDermott, D.
    Lewis, L.
    Voss, M. H.
    Sharma, P.
    Pal, S. K.
    Razak, A.
    Kollmannsberger, C. K.
    Heng, D.
    Spratlin, J.
    McHenry, B.
    Gagnier, P.
    Amin, A.
    ANNALS OF ONCOLOGY, 2016, 27
  • [34] Phase II trial of intermittent therapy in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with front-line ipilimumab and nivolumab (Ipi/Nivo).
    George, Laeth
    Wei, Wei
    Diaz-Montero, C. Marcela
    Martin, Allison
    Vyas, Neil
    Basu, Arnab
    Beckermann, Katy
    Nizam, Amanda
    Wee, Christopher Eing
    Gilligan, Timothy D.
    Gupta, Shilpa
    Rini, Brian I.
    Ornstein, Moshe Chaim
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [35] Combination nivolumab and ipilimumab with and without camu camu in first-line treatment of metastatic renal cell carcinoma (mRCC).
    Barragan-Carrillo, Regina
    Chawla, Neal Shiv
    Salgia, Nicholas
    Meza, Luis A.
    Zengin, Zeynep Busra
    Li, Xiaochen
    Dizman, Nazli
    Ebrahimi, Hedyeh
    Hsu, Joann
    Castro, Daniela V.
    Mercier, Benjamin D.
    Dorff, Tanya B.
    Tripathi, Abhishek
    Bergerot, Cristiane Decat
    Bergerot, Paulo Gustavo
    Chehrazi-Raffle, Alex
    Pal, Sumanta Kumar
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : TPS491 - TPS491
  • [36] Low versus low-intermediate risk metastatic renal cell carcinoma (mRCC): Contemporary data from the International mRCC Database Consortium (IMDC).
    Chehade, Razane El Hajj
    Xie, Wanling
    Semaan, Karl
    Eid, Marc
    Machaalani, Marc
    Nawfal, Rashad
    Saad, Eddy
    Saliby, Renee Maria
    Steiner, Clara
    Yekeduz, Emre
    Wells, Connor
    Maj, David
    Zarba, Martin
    Pal, Sumanta Kumar
    Suarez, Cristina
    Takemura, Kosuke
    Basappa, Naveen S.
    Baca, Sylvan C.
    Heng, Daniel Yick Chin
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
  • [37] CLINICAL HETEROGENEITY AMONG FIRST-LINE SUNITINIB PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC) CATEGORIZED AS INTERMEDIATE RISK (IR) GROUP ACCORDING TO THE INTERNATIONAL MRCC DATABASE CONSORTIUM (IMDC) RISK MODEL
    Huynh, L.
    Wells, J. C.
    Graham, J.
    Steinharter, J.
    McGregor, B.
    Donskov, F.
    Bjarnason, G. A.
    Vaishampayan, U.
    Hansen, A.
    Iafolla, M.
    Zanotti, G.
    Chang, R.
    Cheng, W. Y.
    Duh, M. S.
    Heng, D. Y. C.
    VALUE IN HEALTH, 2019, 22 : S59 - S60
  • [38] Real world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
    Stukalin, Igor
    Wells, J. Connor
    Graham, Jeffrey
    Yuasa, Takeshi
    Beuselinck, Benoit
    Kollmannsberger, Christian K.
    Ernst, D. Scott
    Agarwal, Neeraj
    Le, Tri
    Donskov, Frede
    Hansen, Aaron Richard
    Bjarnason, Georg A.
    Srinivas, Sandy
    Wood, Lori
    Alva, Ajjai Shivaram
    Kanesvaran, Ravindran
    Fu, Simon Yuen Fai
    Davis, Ian D.
    Choueiri, Toni K.
    Heng, Daniel Yick Chin
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [39] Systemic treatments in favorable and very favorable risk metastatic renal cell carcinoma (mRCC): Real world evidence from the International mRCC Database Consortium (IMDC)
    Zarba, Martin
    Ferrier, Evan
    Wells, Connor
    El Zarif, Talal
    Basappa, Naveen S.
    Ebrahimi, Hedyeh
    Mckay, Rana R.
    Wood, Lori
    Beuselinck, Benoit
    Suarez, Cristina
    Takemura, Kosuke
    Lalani, Aly-Khan A.
    Li, Haoran
    Spain, Lavinia Anne
    Templeton, Arnoud J.
    Powles, Thomas
    Bjarnason, Georg A.
    de Velasco, Guillermo
    Choueiri, Toni K.
    Heng, Daniel Yick Chin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [40] Impact of treatment line on outcomes with salvage ipilimumab plus nivolumab in metastatic renal cell carcinoma (mRCC).
    Kotecha, Ritesh
    Lee, Chung-Han
    Knezevic, Andrea
    Shah, Neil J.
    Carlo, Maria Isabel
    Feldman, Darren R.
    Patil, Sujata
    Motzer, Robert J.
    Voss, Martin H.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345